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Summary.-Adenosine deaminase (EC 3.5.4.4, ADA) has been assayed in lympho-
cytes, granulocytes and erythrocytes from 45 patients with haematological malig-
nancies. Activities were uniformly low in lymphocytes from patients with chronic
lymphocytic leukaemia. Variable, but abnormal activities were frequently found
in multiple myeloma, untreated lymphoma and leukaemic reticuloendotheliosis.
High values were observed in lymphocytes from patients with lymphoma during
intensive combination chemotherapy. ADA levels in lymphocytes were not cor-
related with levels in granulocytes or erythrocytes. ADA was elevated in blasts
of patients with acute lymphocytic and myelogenous leukaemias but the ranges
of activities per cell were so similar that ADA assay is unlikely to be of major help
in distinguishing the two diseases.
WE HAVE assayed adenosine deaminase
(EC 3.5.4.4, ADA) in lymphocytes,
granulocytes and erythrocytes from pa-
tients with a wide variety of haemato-
logical malignancies. The original work-
ing hypothesis was that ADA might be
low in adults with haematological neo-
plasms and acquired immunodeficiency,
since decreased to absent activity of ADA
in erythrocytes and lymphocytes is asso-
ciated with an inherited, autosomal reces-
sive form of immunodeficiency disease
ofchildhood (Giblett et al., 1972; Parkman
et al., 1975). Decreased levels of ADA
have been reported in lymphoid cells
from the peripheral blood of children
with acute (Zimmer, Khalifa and Light-
body, 1975) and adults with chronic
(Scholar and Calabresi, 1973; Tung et
al., 1974) lymphocytic leukaemia, most
of whom would be immunodeficient to
some degree.
High values of ADA occur in the
blast cells of patients with acute lympho-
cytic, acute myeloid, chronic mveloid and
chronic myeloid blastic crisis leukaemia,
(Smyth and Harrap, 1975). Because
ADA was usually higher in lymphoblasts
than myeloblasts, Smyth and Harrap
postulated that measurement of ADA
might be useful diagnostically in the
undifferentiated acute leukaemias. We
also find very high ADA activities in
blasts in the acute leukaemias but the
range of values observed is so broad that
no clear distinction between myelogenous
and lymphocytic leukaemia can be made.
Patients with chronic lymphocytic leuk-
aemia uniformly have low ADA in
lymphocytes so that measurement of
ADA might be of diagnostic help in
evaluating a mild lymphocytosis of un-
known cause.
MATERIALS AND METHODS
Informed consent wAas obtained from
blood donors. The project was approved by
the Committee on Human Investigation of
the University of Kentucky and the Lexing-
ton Veterans Administration Hospital.
Methods for assay of ADA in cells of peri-
pheral blood have been described in more
detail in an earlier publication (Coleman and
Hutton, 1975a).ADENOSINE DEAMINASE
Cell separation and preparation of ex-
tracts.-Fractionation oflymphocytes, granu-
locytes and erythrocytes was routinely
carried out on 10-20 ml of freshly drawn,
heparinized blood. Erythrocytes were separ-
ated from leucocytes by dextran sedimenta-
tion and the leucocyte fraction was then
layered on to a Ficoll-Hypaque gradient
(Boyum, 1968) for centrifugal separation of
lymphocytes and polymorphonuclear leuco-
cytes. Purified cells were washed twice
with phosphate buffered saline and centri-
fuged at low speed so that platelets could
be removed. Monocytes contaminating the
lymphocytes were then removed by incubat-
ing the lymphocyte fraction for 4 h at 37°C
in tissue culture flasks containing RPMI-1640
tissue culture medium and serum. Mono-
cytes rapidly adhere to the surface of the
flask and the lymphocytes can then be
decanted. Purified lymphocytes were wash-
ed an additional time in phosphate buffered
saline. Cells were counted on a Coulter
Counter, pelleted and frozen at -70°C until
used. The morphology and types of cells
in each fraction were monitored by examina-
tion of smears of cells on slides stained with
Wright's stain. ADA activity in frozen cells
remained stable for at least several months.
For enzyme assay, pellets of cells were
thawed and resuspended in 50 mmol/l potas-
sium phosphate buffer, pH 7 0, containing
2.5% Triton X-100 and 1 mmol/l mercapto-
ethanol. Lymphocytes or granulocytes were
suspended at a density of 5 x 106 cells/ml,
erythrocytes at 1 X 108 cells/ml. Resuspen-
sion in the dilute buffer was sufficient to
lyse the erythrocytes. Lymphocytes and
granulocytes were disrupted by homogeniza-
tion of the cell suspensions with 50 strokes
of a motor-driven Teflon pestle and glass
homogenizer. Lysates or homogenates were
centrifuged at 12,000 g for 10 min and the
supernatant fraction was assayed for adeno-
sine deaminase activity. To prepare more
concentrated extracts for study on sucrose
density gradients, suspensions of over 108
cells/ml were sonicated in homogenization
buffer and then centrifuged.
Assay of adenosine deaminase.-Adeno-
sine deaminase levels in the cell extracts
were measured by following the conversion
of 14C-adenosine to 14C-inosine (Coleman and
Hutton, 1975a). The reaction mixture con-
tained 50 mmol/l potassium phosphate buffer,
pH 7-0, and 0-25 mmol/l 14C-adenosine
(Schwarz/Mann, sp. act. 3150 ct/min/nmol).
The apparent Km of the ADA for adenosine
was estimated to be 5 X 10-5mol so that
maximal velocity is achieved in our system.
Assay was performed by mixing 25 ,ud of
tissue extract with 100 ,ul of the reaction
mixture, incubating at 37°C and withdraw-
ing 20 ,A aliquots at 5, 10, 15 and 20 min.
The aliquots were spotted on to strips of
Whatman DE-81 chromatography paper
along with 5 ,ul of non-radioactive inosine
(2 mg/ml). The strips were chromatographed
for 1 h in 1 mmol/l ammonium formate by
descending chromatography. They were
then dried in an oven at 80°C. The inosine
spots were located with an ultraviolet lamp,
cut out and counted in toluene-0 4%
BBOT (2.5-bis-2-(5-tert-butylbenzoxazolyl)-
thiophene) cocktail using a scintillation
counter. One unit of enzyme activity is
equal to 1 nmol 14C-inosine produced per
min. Specific activity is expressed as units
of activity per 108 cells.
Sucrose gradients.-5-20% (w/v) sucrose
gradients were prepared in 25 mmol/l Tris
Cl, pH 8-0, 500 mmol/I NaCl, 1 mmol/l
mercaptoethanol and 1 mmol/l EDTA. 0'2
ml samples of the cell extracts were dialysed
several hours against the same buffer without
the sucrose and layered on top of the gra-
dients. The gradients were centrifuged at
40,000 rev/min for 16 h at 4°C in a Spinco
SW 50.1 rotor. Twenty fractions (0.25 ml)
were collected from each gradient by dis-
placement with 50% sucrose. Each fraction
was assayed for adenosine deaminase activity
by adding 10 ,ul of the gradient fraction to
50 ,ul of adenosine deaminase reaction mix.
RESULTS
A survey of adenosine deaminase
activities in erythrocytes, granulocytes
and lymphocytes from normal people and
patients with haematological diseases is
presented in Table I. The normal group
consisted of 22 adults, ranging in age
from 23 to 60 years, who had no evidence
of malignant disease. The level of acti-
vity in normal lymphocytes ranged from
103 to 205 U/108 cells with a mean of
144 and a standard error of 5. ADA
levels in lymphocytes of 5 patients with
untreated chronic lymphocytic leukaemia
(CLL) ranged from 31 to 80 u/108 cells,
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which is significantly below the normal
range (Tables I and II, P < 0-01 by
Student's " t " test). Most of these
patients had minimal disease without
evidence of gross organomegaly, haemo-
lytic anaemia or other complications.
Patients with longstanding or aggressive
CLL had similar low activities of ADA
in their lymphocytes. These patients
were being treated with alkylating agents,
steroids and other agents. Antileukaemic
therapy and control of gross disease did
not result in increased levels of ADA in
lymphocytes (Table II). There were no
TABLE I.-Adenosine Deaminase Activities in Normal and Pathological States*
Group (N)
Normal (22)
Leukaemia
Chronic lymphocytic, untreated (5)
Chronic lymphocytic, treatingt (4)
Leukaemic reticuloendotheliosis* (2)
Acute lymphosarcoma-cell (1)
Acute lymphocytic (7)
Acute myelogenous (6)
Lymphoma
Hodgkin's, untreated (3)
Hodgkin's, treatingt (3)
Hodgkin's, remissiont (1)
Non-Hodgkin's, untreated (3)
Non-Hodgkin's, treatingt (4)
Non-Hodgkin's, remissiont (3)
Multiple myeloma, untreated (3)
Age
range
23-60
47-63
41-80
40-51
30
3-17
19-83
17-52
38-72
52
51-78
17-70
45-48
54-60
Adenosine deaminase (u/108 cells)
Lymphocytes Granulocytes Erythrocytes Blasts
144±5 84±4 3-8±03 3
54±9
55±15
82±28
146±9
246±46
129
166±64
290±59
156± 19
112± 14
74±5 3-9±07 -
76±7 4-1±0-7 7
88 3-7±0-2 2
5-9 2700
860±312
- 5-1±0-6 513±89
88±2
89± 11
90
89±12
98±4
92±5
77±16
4-4±0- 9
4-5±0-2
5 -3
3 -00-2
4- 1±0- 3
5-0±0-8
5-0±1-4
* The number of individuals in each group is indicated in parenthesis. Age range is given in years.
Cells were obtained from peripheral blood and adenosine deaminase values are expressed as the mean
+ s.e., except for leukaemic reticuloendotheliosis which is mean ± range. Patients were not receiving
chemotherapy or radiation therapy except where indicated.
t Patients were receiving one or more cancer chemotherapeutic agents at the time blood was obtained.
Specific information about the drugs used in one group of patients, CLL, presented in Table II. Because
of the complexity ofthe chemotherapy and the lack ofcorrelation between ADA and specific agents, further
details about treatment are omitted.
t Patients in remission had received extensive chemotherapy or radiation therapy, but this had been
discontinued at least one year before study. At the time blood was obtained there was no clinical evidence
of recurrence of lymphoma.
TABLE II.-Adenosine Deaminase Activities in Lymphocytesfrom
Patients with Chronic Lymphocytic Leukaemia
Age (years) Duration of disease
and sex (years)*
63, F 2
47, M 0
57, M 1
50, M 0
60, M 0
61, M 8
62, M 5
80, M 3
41, M 5
Chemotherapyt
None
None
None
None
None
Chl, Vin, Pred, 6TG
Cyc, Vin, Pred, Chl, Pro
Chl, Pred
Cyc, Vin, Pred
Adenosine deaminaset
(u/108 lymphocytes)
46
31
42
80
71
37
92
26
63
* Duration of disease is time from diagnosis by haematological evaluation and is not estimated from
the patient's history of possible earlier signs and symptoms.
t Chemotherapeutic agents received by the patient as treatment of his leukaemia. Chl, chlorambucil;
Vin, vincristine; Pred, prednisone; 6TG, 6-thioguanine; Cyc, cyclophosphamide; Pro, procarbazine.
t Assay of ADA in lymphocytes is very reproducible and repetitive determinations on blood specimens
from the same donor are usually ± 10% of the mean (Coleman and Hutton, 1975a).
Patient
1
2
3
4
5
6
7
8
9
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apparent correlations between therapy or
duration of disease and ADA values,
contrary to the report of Tung et al.
(1974) who found that ADA levels in-
creased toward normal in treated cases
ofCLL. ADA activities remained normal
in granulocytes and erythrocytes of pa-
tients with treated and untreated CLL
(Table I). Two patients with untreated
leukaemic reticuloendotheliosis were stud-
ied. In one case the ADA activity in
lymphocytes was very low (54 U/108 cells)
whereas in the second patient the value
was higher (110 u/108 cells) and closer to
normal (Table I).
Blasts from patients with acute lym-
phocytic (ALL) and acute myelogenous
(AML) leukaemia had levels of ADA
activity 2 to 10-fold higher than lympho-
cytes of normal individuals (Table I).
The activities observed in lymphoblasts
varied more from patient to patient than
did activities in myeloblasts, but in
neither type of acute leukaemia did
blasts have ADA activities comparable
with those present in cells of normal
peripheral blood. These observations dis-
agree with the report of Zimmer et al.
(1975) who found decreased levels of
ADA in peripheral lymphoid cells from
patients with acute lymphocytic leuk-
aemia in relapse. The lymphoid cells
consisted of a mixed population of
lymphoblasts and lymphocytes. Our ob-
servations, however, agree with those of
Smyth and Harrap (1975).
Lymphoma is frequently associated
with impaired immunological function,
especially defective cellular immunity.
Whether lymphocytes have abnormal
levels of ADA in lymphoma has not
been reported. Lymphocytes from 3 un-
treated patients with Hodgkin's disease
had normal ADA activities (Table I).
Each of these patients had stage IIA
disease. ADA activities in lymphocytes
from people with untreated non-Hodgkin's
lymphomata were variable, with values
of 88 and 293 in lymphocytic lymphomata,
175 in a localized histiocytic lymphoma
of the stomach, and 117 in a mixed
histiocytic-lymphocytic lymphoma. Com-
bination chemotherapy of both Hodgkin's
and non-Hodgkin's lymphomata was asso-
ciated with elevation of ADA activities
in lymphocytes. Mean values ± s.e. for
patients receiving chemotherapy were
246 ± 46 in Hodgkin's disease and
290 ± 59 in non-Hodgkin's lymphoma.
Each of these values differs significantly
(P < 0.01, Student's " t " test) from
normal. A number of different drug
regimens were being employed in patients
at various stages of their disease, in-
cluding alkylating agents, vincristine and
prednisone combinations, bleomycin, ad-
riamycin and methotrexate. The obser-
vation that ADA values are elevated in
lymphocytes of patients receiving chemo-
therapy for lymphoma appears consistent
for commonly used drug regimens and
contrasts with the values ofADA observed
in patients with chronic lymphocytic
leukaemia on chemotherapy. Four pa-
tients with lymphoma in clinical remission
to whom chemotherapy had not been
administered for at least one year had
normal values ofADA activity. Lympho-
cytes had low levels of ADA in 3 people
with untreated multiple myeloma.
Regardless of changes in ADA activity
in lymphocytes, no consistent abnor-
malities were observed in erythrocytes or
granulocytes (Table I). ADA values in
extracts of granulocytes were remarkably
constant in all the groups studied. There
was greater variability in the red cell
ADA values but in no group was there
an extreme deviation from the control
values. Because ADA activity is so
low in erythrocytes compared with nucle-
ated cells, minor degrees of contamination
oferythrocytes with nucleated cells would
elevate the apparent red cellADA activity.
Such contamination was monitored both
by morphological examination of cell
preparations and by differential particle
counts before and after detergent treat-
ment of cell suspensions. Contamination
of erythrocytes with nucleated cells was
generally less than 0.2% and ADA values
in erythrocytes were corrected to eliminate
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the contribution of granulocytes and
lymphocytes.
Since ADA activities were much higher
in lymphoblasts of children with ALL
than in normal lymphocytes, the effect
of chemotherapy on ADA values was
monitored in 5 children. Initial peri-
pheral leucocyte counts ranged from
40,000 to 400,000/ldl with 80-95% lympho-
blasts. The specific activities of ADA in
the blasts ranged from 349 to 2650 u/108
cells. The capacity of blasts from these
patients to form E rosettes with sheep
red blood cells has been reported (Coleman
et al., 1976). ADA values in blasts
forming E rosettes were 549, 2650 and
345 u/108 cells; values in blasts not
forming E rosettes were 562 and 349 u/108
cells. As seen in Fig. 1, there is a rapid
decrease in ADA levels during induction
of remission with vincristine and pred-
nisone. By 21 days after induction
therapy was begun, lymphoblasts had
z
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FIG. 1. ADA activities in the lymphocyte-
lymphoblast fraction from the peripheral
blood of patients with acute lymphocytic
leukaemia. Induction chemotherapy with
vincristine and prednisone was begun on
Day 1. Initially the lymphocyte fraction
contained at least 80% lymphoblasts but
this value decreased to 00% by Day 21, after
which only mature lymphocytes were
found. Different symbols represent dif-
ferent patients.
disappeared from the peripheral blood
ofeach patient and the peripheral lympho-
cytes appeared morphologically mature.
ADA values in these lymphocytes had
returned to normal levels.
It seemed most likely that differences
in the activity of ADA per lymphocyte
in CLL or per lymphoblast in ALL
compared with the activity in normal
lymphocytes were due to changes in the
level of the enzyme rather than to the
presence of inhibitors or activators in
homogenates. In order to investigate
this possibility, a series of mixing experi-
ments was performed using extracts of
normal lymphocytes, lymphocytes from
CLL and lymphoblasts from ALL. In
all cases the enzymatic activities of the
mixtures were as expected from addition
ofthe separate activities with no evidence
of inhibitors or activators.
Deviation from normal levels of ADA
activity was consistently observed in
lymphocytes of chronic lymphocytic leuk-
aemia and in blast cells of acute myelo-
genous and acute lymphocytic leukaemias.
This observation prompted an investiga-
tion ofpossible alterations in the molecular
weight of the enzyme in association with
these diseases since there are two species
of ADA which differ in molecular weight
(Akedo et al., 1972; Osborne and Spencer,
1973). Cell extracts were sedimented
through 5-20% sucrose gradients, as seen
in Fig. 2. Recovery of ADA activity
from the gradients was greater than
70%. The major species of ADA peaked
in tube 7 with an estimated molecular
weight ofapproximately 40,000. Lympho-
cytesfrom normalpeople (a)andfrom pati-
ents with CLL (b) generally contained a
minor component of ADA with a high
molecular weight. Activity in this com-
ponent generally peaked in tube 19, with
an estimated molecular weight of 200,000.
This species comprises around 5% of the
total ADA activity. Blasts from patients
with AML (c) and ALL (d) had elevated
activities of ADA. When sedimented
through sucrose density gradients, ADA
from these blasts was relatively homo-
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FIG. 2.-Sucrose density gradient sedimentation of adenosine deaminase from sonicates of (a) normal
lymphocytes, (b) lymphocytes of chronic lymphocytic leukaemia, (c) myeloblasts of acute
myelogenous leukaemia, (d) lymphoblasts of acute lymphocytic leukaemia. Note the differences
in scale of the ordinate for the different types of cells.
geneous with maximal activity in tube 7
and little or no activity in tube 19 (Fig. 2).
DISCUSSION
The recent development of a conve-
nient, sensitive radiometric method of
assaying ADA in small numbers of cells
from peripheral blood (Coleman and
Hutton, 1975a) has facilitated our in-
vestigation ofchanges in ADA in haemato-
logical malignancies. One important con-
clusion from our work is that ADA
values in lymphocytes vary in malignant
diseases without associated changes in
erythrocytes or granulocytes. Assays of
one type of cell in the peripheral blood
cannot be used to predict ADA levels in
other types of cells.
ADA activity was low (approximately
35% of normal) in lymphocytes of pa-
tients with chronic lymphocytic leukaemia
(Table II) but was normal in their
erythrocytes and granulocytes. Scholar
and Calabresi (1973) and Tung et al.
(1974) have reported similar results in
lymphocytes. The latter investigators
found that ADA activity increased fol-
lowing chemotherapy, which is not sup-
ported by the data presented in Table II.
In our experience, ADA activities in
lymphocytes of newly diagnosed patients
with chronic lymphocytic leukaemia and
minimal disease are similar to those
observed in patients receiving chemo-
therapy for far advanced disease. Chronic
lymphocytic leukaemia is generally a B
cell disorder and it is of interest that
two other probable disorders of B cells,
multiple myeloma and hairy-cell leuk-
aemia (Catovsky et al., 1974) are also
associated with variable, but low, acti-
vities of ADA in peripheral lymphocytes
(Table I).
Elevated values of ADA are regularly
found in the lymphocytes of patients
with lymphoma who are receiving in-
tensive combination chemotherapy. This
was unexpected since lymphocytes from
patients with chronic lymphocytic leuk-
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aemia who were receiving similar drugs
had low levels ofADA. Newly diagnosed
patients with lymphoma, or those who
have completed chemotherapy, rarely
have abnormal values of ADA. One
patient with a poorly differentiated lym-
phocytic lymphoma developed lympho-
sarcoma-cell leukaemia. Blasts from this
patient's blood contained very high levels
of ADA, resembling human thymocytes
and cells of lymphoblastoid cell lines
(Coleman and Hutton, 1975b).
ADA activity was elevated in blasts
from patients with acute lymphocytic
and acute myelogenous leukaemia. Dif-
ferences in the specific activity per cell
were insufficient and too variable to
permit use of ADA as a biochemical
marker for distinguishing the two types
of blasts (Table I). We monitored ADA
activity in the blood of 5 children during
chemotherapy for acute lymphocytic leuk-
aemia in order to see whether it could
serve as a biochemical marker for the
presence of abnormal cells in the peri-
pheral blood. ADA values in peripheral
lymphoid cells returned to normal as
remission was achieved. There was no
suggestion that ADA would be a useful
biochemical marker of disease activity
and completeness ofremission.
The cause of alterations of ADA
activity in lymphoproliferative diseases is
not clear. Certainly variation in the
stage of immunological maturation of the
circulating lymphocyte may be important
because leukaemic lymphoblasts, human
thymocytes and lymphoblastoid cell lines
all have high levels of ADA, when com-
pared with normal mature circulating
lymphocytes (Coleman and Hutton,
1975b). Elevated levels of ADA in lym-
phocytes would indicate changes in the
degree of immunological activity com-
pared to normal. Low values seem gener-
ally to be associated with abnormal B cell
proliferation.
Our conclusion after assaying ADA
in lymphocytes, granulocytes and erythro-
cytes of 45 patients with haematological
disease is that the procedure is too
laborious for the limited amount of in-
formation derived. Assay of the enzyme
is rapid and inexpensive, lending itself to
population surveys. It is the cell separa-
tion procedure that is time-consuming
and expensive, prohibiting routine survey
of populations. Cell separation tech-
niques are necessary, however, because
of the lack of correlation among erythro-
cyte, granulocyte and lymphocyte ADA
levelsexceptin case ofprofoundhereditary
deficiency due presumably to a structural
mutation in the common catalytic unit.
Even the lowest values of ADA observed
in adult lymphocytes did not seem far
enough below normal to cause disordered
purine catabolism which could affect
lymphocyte function and explain acquired
immunodeficiency. This shouldbe tested,
however, by measuring the purine content
of lymphocytes in chronic lymphocytic
leukaemia.
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